CSIMarket
 


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 
 

GNCA's Net Income Growth by Quarter and Year

Genocea Biosciences Inc 's Net Income results by quarter and year




GNCA Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -13.28 -14.99 -9.36
III Quarter September - -3.62 -4.56 -7.53
II Quarter June - -4.31 -11.32 -6.50
I Quarter March -15.98 -11.98 -12.85 -15.57
FY   -15.98 -33.19 -43.72 -38.96



GNCA Net Income first quarter 2022 Y/Y Growth Comment
Genocea Biosciences Inc in the first quarter 2022 recorded net loss of $ -15.98 millions.

According to the results reported in the first quarter 2022, Genocea Biosciences Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Genocea Biosciences Inc ' s Net Income no change of % ranks overall at the positon no. in the first quarter 2022.




GNCA Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Genocea Biosciences Inc 's first quarter 2022 Net Income $ -15.98 millions GNCA's Income Statement
Genocea Biosciences Inc 's first quarter 2021 Net Income $ -11.98 millions Quarterly GNCA's Income Statement
New: More GNCA's historic Net Income Growth >>


GNCA Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genocea Biosciences Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Net Income Comment
Recent net loss of -15.98 millions by Genocea Biosciences Inc look even worse compare to the -13.28 millions net loss a quarter before.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Net Income growth. While Genocea Biosciences Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNCA's I. Quarter Q/Q Net Income Comment
Recent net loss of -15.98 millions by Genocea Biosciences Inc look even less good if you take a look at net loss -13.28 millions a quarter before.

Within Biotechnology & Pharmaceuticals industry Genocea Biosciences Inc achieved highest sequential Net Income growth. While Genocea Biosciences Inc 's Net Income growth quarter on quarter, overall rank is .


Genocea Biosciences Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Net Income 12 Months Ending $ -37.19 $ -33.20 $ -34.90 $ -35.83 $ -42.84
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment


Genocea Biosciences Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment


Genocea Biosciences Inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
GNCA's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for GNCA's Competitors
Net Income Growth for Genocea Biosciences Inc 's Suppliers
Net Income Growth for GNCA's Customers

You may also want to know
GNCA's Annual Growth Rates GNCA's Profitability Ratios GNCA's Asset Turnover Ratio GNCA's Dividend Growth
GNCA's Roe GNCA's Valuation Ratios GNCA's Financial Strength Ratios GNCA's Dividend Payout Ratio
GNCA's Roa GNCA's Inventory Turnover Ratio GNCA's Growth Rates GNCA's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2022
Conmed Corporation51.88%$ 51.876 millions
Becton Dickinson And Company51.33%$ 51.333 millions
Iqvia Holdings Inc 49.77%$ 49.770 millions
Charles River Laboratories International inc 48.94%$ 48.942 millions
Co diagnostics Inc 48.31%$ 48.305 millions
Phibro Animal Health Corporation45.46%$ 45.457 millions
Abcellera Biologics Inc 43.81%$ 43.808 millions
Medpace Holdings Inc 41.58%$ 41.576 millions
Eli Lilly And Company40.40%$ 40.404 millions
Abbott Laboratories36.48%$ 36.475 millions
Merck and Co Inc 35.37%$ 35.374 millions
Bio techne Corp32.47%$ 32.470 millions
The Pennant Group Inc 26.83%$ 26.835 millions
Abbvie inc 26.39%$ 26.385 millions
Tenet Healthcare Corp26.13%$ 26.126 millions
Glucotrack Inc 20.91%$ 20.907 millions
Syneos Health Inc 19.24%$ 19.244 millions
Utah Medical Products Inc16.87%$ 16.865 millions
Ufp Technologies Inc 16.69%$ 16.695 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com